Ann Rheum Dis 1999;58:79-84 ( February )

Extended reports

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis Cees J Haagsma,^a Henk J Blom,^b Piet L C M van Riel,^a Martin A van't Hof,^c Belinda A J Giesendorf,^b Dinny van Oppenraaij-Emmerzaal,^b Levinus B A van de Putte^a

^a Department of Rheumatology, ^b Laboratory of Paediatrics and Neurology, ^c University Hospital Nijmegen, the Netherlands Department of Statistical Consultation, University of Nijmegen, the Netherlands

Correspondence to: Dr C J Haagsma, Department of Rheumatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Accepted for publication 13 October 1998

OBJECTIVETo study the influence of sulphasalazine (SSZ), methotrexate (MTX), and the combination (COMBI) of both on plasma homocysteine and to study the relation between plasma homocysteine and their clinical effects.
METHODS105 patients with early rheumatoid arthritis (RA) were randomised between SSZ (2-3 g/day), MTX (7.5-15 mg/week), and the COMBI (same dose range) and evaluated double blindly during 52 weeks. Plasma homocysteine, serum folate concentrations, and vitamin B12 were measured. The influence of the C677T mutation of the enzyme methylenetetrahydrofolatereductase (MTHFR) gene was analysed.
RESULTSA slight trend towards increased efficacy and an increased occurrence of minor gastrointestinal toxicity was present in the COMBI group, no differences existed clinically between SSZ and MTX. Only a slight and temporary increase in plasma homocysteine was found in the SSZ group, in contrast with the persistent rise in the MTX group and the even greater increase in the COMBI patients. Patients homozygous for the mutation in the MTHFR gene had significantly higher baseline homocysteine, heterozygous MTHFR genotype induced a significantly higher plasma homocysteine at week 52 compared with no mutation. No correlation was found between clinical efficacy variables and homocysteine. Patients with gastrointestinal toxicity had a significantly greater increase in homocysteine.
CONCLUSIONA persistent increase in plasma homocysteine concentrations was observed in patients treated with MTX alone and more pronounced in combination with SSZ, in contrast with SSZ alone. An increase in plasma homocysteine is related to the C677T mutation in MTHFR. A relation in the change in homocysteine concentrations with (gastrointestinal) toxicity was found, no relation with clinical efficacy existed.

Keywords: homocysteine; methotrexate; sulphasalazine; arthritis

---

© 1999 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ma, M. H. Y., Kingsley, G. H., Scott, D. L. (2009). A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 0: kep331v1-kep331 [Abstract] [Full Text]  
• Inoue, K., Nakai, Y., Ueda, S., Kamigaso, S., Ohta, K.-y., Hatakeyama, M., Hayashi, Y., Otagiri, M., Yuasa, H. (2008). Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G660-G668 [Abstract] [Full Text]  
• Nakai, Y., Inoue, K., Abe, N., Hatakeyama, M., Ohta, K.-y., Otagiri, M., Hayashi, Y., Yuasa, H. (2007). Functional Characterization of Human Proton-Coupled Folate Transporter/Heme Carrier Protein 1 Heterologously Expressed in Mammalian Cells as a Folate Transporter. J. Pharmacol. Exp. Ther. 322: 469-476 [Abstract] [Full Text]  
• Hall, F. C., Dalbeth, N. (2005). Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology (Oxford) 44: 1473-1482 [Abstract] [Full Text]  
• Yozai, K., Shikata, K., Sasaki, M., Tone, A., Ohga, S., Usui, H., Okada, S., Wada, J., Nagase, R., Ogawa, D., Shikata, Y., Makino, H. (2005). Methotrexate Prevents Renal Injury in Experimental Diabetic Rats via Anti-Inflammatory Actions. J. Am. Soc. Nephrol. 16: 3326-3338 [Abstract] [Full Text]  
• Choy, E. H. S., Smith, C., Dore, C. J., Scott, D. L. (2005). A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 44: 1414-1421 [Abstract] [Full Text]  
• Ranganathan, P, Berkun, Y, Friedman, G, Ben-Yehuda, A (2005). Methotrexate related adverse effects in patients with RA * Authors' reply. Ann Rheum Dis 64: 968-968 [Full Text]  
• Hoekstra, M, Haagsma, C J, Doelman, C J A, van de Laar, M A F J (2005). Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 64: 141-143 [Abstract] [Full Text]  
• Berkun, Y, Levartovsky, D, Rubinow, A, Orbach, H, Aamar, S, Grenader, T, Abou Atta, I, Mevorach, D, Friedman, G, Ben-Yehuda, A (2004). Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63: 1227-1231 [Abstract] [Full Text]  
• Goodson, N. J., Silman, A. J., Pattison, D. J., Lunt, M., Bunn, D., Luben, R., Day, N., Khaw, K.-T., Symmons, D. P. M. (2004). Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 43: 731-736 [Abstract] [Full Text]  
• Whittle, S. L., Hughes, R. A. (2004). Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 43: 267-271 [Abstract] [Full Text]  
• Vaudo, G, Marchesi, S, Gerli, R, Allegrucci, R, Giordano, A, Siepi, D, Pirro, M, Shoenfeld, Y, Schillaci, G, Mannarino, E (2004). Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63: 31-35 [Abstract] [Full Text]  
• Lazzerini, P E, Capecchi, P L, Bisogno, S, Galeazzi, M, Marcolongo, R, Pasini, F L. (2003). Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment. Ann Rheum Dis 62: 694-695 [Full Text]  
• Kitas, G. D., Erb, N. (2003). Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42: 607-613 [Full Text]  
• Rampersaud, G. C., Kauwell, G. P.A., Bailey, L. B. (2003). Folate: A Key to Optimizing Health and Reducing Disease Risk in the Elderly. J. Am. Coll. Nutr. 22: 1-8 [Abstract] [Full Text]  
• Ranganathan, P, Eisen, S, Yokoyama, W M, McLeod, H L (2003). Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?. Ann Rheum Dis 62: 4-9 [Abstract] [Full Text]  
• De Bree, A., Verschuren, W. M. M., Kromhout, D., Kluijtmans, L. A. J., Blom, H. J. (2002). Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease. Pharmacol. Rev. 54: 599-618 [Abstract] [Full Text]  
• Siva, C., Yokoyama, W. M., McLeod, H. L. (2002). Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field. Rheumatology (Oxford) 41: 1273-1279 [Abstract] [Full Text]  
• Post, A. M., Katsikis, P. D., Tait, J. F., Geaghan, S. M., Strauss, H. W., Blankenberg, F. G. (2002). Imaging Cell Death with Radiolabeled Annexin V in an Experimental Model of Rheumatoid Arthritis. JNM 43: 1359-1365 [Abstract] [Full Text]  
• van Ede, A. E., Laan, R. F. J. M., Blom, H. J., Boers, G. H. J., Haagsma, C. J., Thomas, C. M. G., de Boo, T. M., van de Putte, L. B. A. (2002). Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41: 658-665 [Abstract] [Full Text]  
• Hamilton, J, McInnes, I B, Thomson, E A, Porter, D, Hunter, J A, Madhok, R, Capell, H A (2001). Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 60: 566-572 [Abstract] [Full Text]  
• Erb, N., Kitas, G. D. (2001). Homocysteine modulation as a reason for continuous folic acid supplementation in methotrexate-treated rheumatoid arthritis patients. Rheumatology (Oxford) 40: 715-716 [Full Text]  
• MANZI, S., WASKO, M. C. M, MANZI, S. (2000). Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 59: 321-325 [Full Text]  
• Vollset, S. E., Nygard, O., Refsum, H., Ueland, P. M. (2000). Coffee and homocysteine1. Am. J. Clin. Nutr. 71: 403-404 [Full Text]